

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6104468

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIOTECH RNA PHARMACEUTICALS GMBH	12/17/2015
RECEIVING PARTY DATA	
Name:	BIONTECH AG
Street Address:	AN DER GOLDGRUBE 12
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55131
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16117197
CORRESPONDENCE DATA	
Fax Number:	(678)420-9301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6784209300
Email:	salmona@ballardspahr.com
Correspondent Name:	SANDRA A. SCIASCIA-ZIRGER
Address Line 1:	999 PEACHTREE STREET
Address Line 2:	BALLARD SPAHR LLP, SUITE 100
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	37592.0001U2
NAME OF SUBMITTER:	SANDRA A. SCIASCIA-ZIRGER
SIGNATURE:	/Sandra A. Sciascia-Zirger/
DATE SIGNED:	05/13/2020
Total Attachments: 2	
source=37592_0001U2_BiontechRna_to_Biontech#page1.tif	
source=37592_0001U2_BiontechRna_to_Biontech#page2.tif	

ASSIGNMENT

WHEREAS, **BIONTECH RNA PHARMACEUTICALS GMBH**, whose principal address is An der Goldgrube 12, Mainz, Germany 55131, is owner of the entire right, title and interest in new and useful improvements in “**AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES,**” for which a United States National Phase Application based on International Application No. PCT/EP2013/003399, filed November 12, 2013, which claims the benefit of International Application Nos. PCT/EP2013/002270, filed July 30, 2013 and PCT/EP2012/004712, filed November 13, 2012 was filed on May 13, 2015, and assigned United States Patent Application No. 14/442,445; and

WHEREAS, **BIONTECH AG**, whose principal address is An der Goldgrube 12, Mainz, Germany 55131 is desirous of acquiring the entire interest in the same;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, **BIONTECH RNA PHARMACEUTICALS GMBH** hereby does sell, assign and transfer unto said **BIONTECH AG**, the entire right, title and interest in and to said invention and application throughout the world, including, without limitation, any Letters Patent which may issue thereon, and any subsequent application claiming priority to the above-identified application, reissue, reexamination, divisional, continuation-in-part, extension or continuation thereof and all rights of priority under the International Convention arising from said application; the same for **BIONTECH AG**'s legal representatives and assigns, as fully and entirely as the same would have been held by us had this assignment and sale not been made;

AND, **BIONTECH RNA PHARMACEUTICALS GMBH** hereby binds itself, its legal representatives and assigns properly to execute without further consideration any and all

applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect, the sale, assignment, transfer and conveyance hereby made or intended to be made and generally do everything possible to aid BIONTECH AG, its legal representatives and assigns, to obtain and enforce proper protection for said invention in all countries throughout the world.

IN WITNESS WHEREOF, I have executed this Assignment this 10th day of September, 2015.

BIONTECH RNA PHARMACEUTICALS
GMBH

By: [Signature] (L.S.)

Title: Managing Director (CEO)

WITNESSETH:

1. [Signature]
Name: _____
Address: _____
5524

2. [Signature]
Name: Michael Kruse
Address: 1er Brüel 3
55130 Mainz